We are live on ! Find out more
HOOK

HOOKIPA Pharma

Delisted

HOOK was delisted on the 7th of August, 2025.

72 hedge funds and large institutions have $74.2M invested in HOOKIPA Pharma in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 24 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

1% more funds holding

Funds holding: 7172 (+1)

0.05% more ownership

Funds ownership: 4.81%4.86% (+0.05%)

8% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 24

35% less capital invested

Capital invested by funds: $114M → $74.2M (-$40.3M)

37% less call options, than puts

Call options by funds: $516K | Put options by funds: $825K

Holders
72
Holders Change
+1
Holders Change %
+1.41%
% of All Funds
1.26%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
10
Increased
22
Reduced
24
Closed
9
Calls
$516K
Puts
$825K
Net Calls
-$309K
Net Calls Change
+$1.54M
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$368K +$27.9K +385 +7%
Citadel Advisors
27
Citadel Advisors
Florida
$360K -$22.3K -308 -5%
Dimensional Fund Advisors
28
Dimensional Fund Advisors
Texas
$345K -$13.1K -180 -3%
Los Angeles Capital Management
29
Los Angeles Capital Management
California
$298K +$95.4K +1,316 +35%
PP
30
PDT Partners
New York
$290K +$358K +4,930 New
Bank of America
31
Bank of America
North Carolina
$287K -$58.7K -810 -14%
Charles Schwab
32
Charles Schwab
California
$281K
Susquehanna International Group
33
Susquehanna International Group
Pennsylvania
$218K -$213K -2,943 -44%
Morgan Stanley
34
Morgan Stanley
New York
$198K -$838K -11,553 -77%
CSS
35
Cubist Systematic Strategies
Connecticut
$151K +$14.3K +197 +8%
Walleye Trading
36
Walleye Trading
New York
$133K +$164K +2,264 New
ECM
37
ExodusPoint Capital Management
New York
$130K +$7.03K +97 +5%
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
$96K -$3.19K -44 -3%
Barclays
39
Barclays
United Kingdom
$96K +$101K +1,394 +574%
Mitsubishi UFJ Asset Management
40
Mitsubishi UFJ Asset Management
Japan
$92K
Citigroup
41
Citigroup
New York
$88K -$7.98K -110 -7%
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$87K +$10.5K +145 +11%
Goldman Sachs
43
Goldman Sachs
New York
$82K -$149K -2,057 -60%
Simplex Trading
44
Simplex Trading
Illinois
$77K +$725 +10 +1%
Connor, Clark & Lunn Investment Management (CC&L)
45
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$76K +$93.3K +1,287 New
HS
46
HighVista Strategies
Massachusetts
$71K +$87.4K +1,205 New
ASN
47
Advisory Services Network
Georgia
$70K +$85.6K +1,180 New
IWM
48
IHT Wealth Management
Illinois
$68K +$145 +2 +0.2%
EMG
49
ETF Managers Group
New Jersey
$66K +$15.4K +213 +24%
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$64K +$508 +7 +0.6%

HOOK Hedge Fund Activity: Q3 2021 in Review

72 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in HOOKIPA Pharma (HOOK) for Q3 2021, worth a combined $74.2M — down 35% from $114M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new HOOK positions and 9 closed out — a net gain of 1 holder — while 22 added to existing stakes and 24 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $1.44M. The largest seller was HHLR Advisors, exiting entirely with an estimated $2.47M sold.

  • 72 institutional investors held HOOKIPA Pharma (HOOK) as of Q3 2021, up from 71 in Q2 2021.
  • Funds reported $74.2M of HOOKIPA Pharma stock for Q3 2021, down 35% quarter-over-quarter.
  • 10 funds opened new HOOKIPA Pharma positions in Q3 2021 and 9 closed out, a net change of +1 holder.
  • The largest HOOKIPA Pharma buyer in Q3 2021 was Fidelity Investments, an estimated $1.44M added.
  • The largest HOOKIPA Pharma seller in Q3 2021 was HHLR Advisors, an estimated $2.47M sold.

Based on aggregated 13F filings for Q3 2021.